FindTrial
Sign In

Study on the mechanism of tumor immune microenvironment in endometrial cancer for effective treatment strategies

Study on the mechanism of tumor immune microenvironment in endometrial cancer for effective treatment strategies

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035730
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-10-02
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

Gold Standard:Clinical outcome
Index test:peripheral&#32
blood&#32
T&#32
-&#32
cell&#32
function&#32
in&#32
immune&#32
microenvironment

Sponsors

Shanghai First Maternity and infant Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who suffered from endometrial cancer

Exclusion criteria

Exclusion criteria: Application of immunosuppressant and related diseases of the immune system cancer

Design outcomes

Primary

MeasureTime frame
overall survival, OS;progression-free survival, PFS;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactLi Bilan

Shanghai First Maternity and infant Hospital

lorrain221@msn.com+86 13761610432

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026